Vol 80, No 3 (2022)
Original article
Published online: 2022-02-15

open access

Page views 5124
Article views/downloads 660
Get Citation

Connect on Social Media

Connect on Social Media

Long-term outcomes in patients after left atrial appendage occlusion: The results from the LAAO SILESIA registry

Krzysztof Myrda1, Witold Streb2, Wojciech Wojakowski3, Jacek Piegza1, Katarzyna Mitręga2, Grzegorz Smolka3, Jolanta Nowak14, Tomasz Podolecki2, Ewa Gasiewska-Żurek3, Alicja Nowowiejska-Wiewióra1, Malwina Smolarek-Nicpoń3, Michał Skrzypek5, Mariusz Gąsior14, Zbigniew Kalarus2
Pubmed: 35167113
Kardiol Pol 2022;80(3):332-338.

Abstract

Background: The benefits of oral anticoagulation (OAC) therapy are undeniable. However, such treatment is contraindicated in 2%–10% of patients. According to the latest guidelines, percutaneous left atrial appendage occlusion (LAAO) may be considered in stroke prevention.
Aims: We analyzed the data of patients from the Polish population, who had undergone LAAO procedures in the Silesian Province based on limited reports.
Methods: The data from the SILCARD database of all patients who underwent LAAO between 2006 and 2019, and the data from the databases of the centers performing the procedures in the Silesian Province were included in the LAAO SILESIA registry. We analyzed the efficacy and safety of the procedure and its relationship with the occurrence of stroke and bleeding in the post-hospital follow-up.
Results: We analyzed 649 patients with the mean values of CHA2DS2-VASc and HAS-BLED scores of 4.1 and 3.2, respectively. The predominant indication for LAAO was a history of bleeding during OAC. The most frequent in-hospital major adverse cardiac events were anemia, which required blood transfusion (5.5%), and pericardial effusion, which was treated either conservatively (0.9%) or interventionally (1.2%). During hospitalization, stroke was detected in 4 patients and three patients died of any cause. LAAO reduced the annual risk of stroke by 84% and the annual risk of bleeding by 27%.
Conclusions: Based on a “real-life” cohort of patients from the Silesian Province, we concluded that LAAO is related to low in-hospital major cardiovascular adverse events. In the long-term follow-up, LAAO reduced the rates of stroke and bleeding. 

References

  1. Tu HTH, Campbell BCV, Christensen S, et al. Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis. 2010; 30(4): 389–395.
  2. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129(8): 837–847.
  3. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962.
  4. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020; 42(5): 373–498.
  5. O'Brien EC, Holmes DN, Ansell JE, et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2014; 167(4): 601–609.e1.
  6. Steinberg BA, Greiner MA, Hammill BG, et al. Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. Cardiovasc Ther. 2015; 33(4): 177–183.
  7. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation. 2002; 105(16): 1887–1889.
  8. Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014; 64(1): 1–12.
  9. Hirnle G, Lewkowicz J, Suwalski P, et al. Effectiveness of surgical closure of left atrial appendage during minimally invasive mitral valve surgery. Kardiol Pol. 2020; 78(11): 1137–1141.
  10. Reddy VY, Doshi SK, Sievert H, et al. PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013; 127(6): 720–729.
  11. Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2016; 11(10): 1170–1179.
  12. Boersma LVA, Schmidt B, Betts TR, et al. EWOLUTION investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016; 37(31): 2465–2474.
  13. Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017; 70(24): 2964–2975.
  14. Kim JS, Lee H, Suh Y, et al. Left atrial appendage occlusion in non-valvular atrial fibrillation in a Korean multi-center registry. Circ J. 2016; 80(5): 1123–1130.
  15. Tzikas A, Holmes DR, Gafoor S, et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies. EuroIntervention. 2016; 12(1): 103–111.
  16. Betts TR, Leo M, Panikker S, et al. Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: A multicenter registry. Catheter Cardiovasc Interv. 2017; 89(3): 484–492.
  17. Brachmann J, Lewalter T, Akin I, et al. Interventional occlusion of left atrial appendage in patients with atrial fibrillation. Acute and long-term outcome of occluder implantation in the LAARGE Registry. J Interv Card Electrophysiol. 2020; 58(3): 273–280.
  18. Roleder T, Hawranek M, Gąsior T, et al. Trends in aortic stenosis diagnosis and treatment in the years 2006–2016 according to the SILesian CARDiovascular (SILCARD) database. Pol Arch Intern Med. 2018; 128(12): 739–745.
  19. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012; 33(12): 1500–1510.
  20. Berti S, Santoro G, Brscic E, et al. Left atrial appendage closure using AMPLATZER™ devices: A large, multicenter, Italian registry. Int J Cardiol. 2017; 248: 103–107.
  21. Kefer J, Aminian A, Vermeersch P, et al. Transcatheter left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: results from the Belgian registry. EuroIntervention. 2018; 13(13): 1603–1611.
  22. Niedziela JT, Parma Z, Pawlowski T, et al. Secular trends in first-time hospitalization for heart failure with following one-year readmission and mortality rates in the 3.8 million adult population of Silesia, Poland between 2010 and 2016. The SILCARD database. Int J Cardiol. 2018; 271: 146–151.
  23. Holmes DR, Reddy VY, Turi ZG, et al. PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009; 374(9689): 534–542.
  24. Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013; 61(25): 2551–2556.
  25. Grygier M, Wojakowski W, Smolka G, et al. [Left atrial appendage occlusion: consensus document of Association of Cardiovascular Interventions and Heart Rhythm Section of Polish Cardiac Society]. Kardiol Pol. 2018; 76(3): 677–697.
  26. Kleinecke C, Park JW, Gödde M, et al. Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet. Cardiol J. 2017; 24(2): 131–138.
  27. Berti S, Pastormerlo LE, Santoro G, et al. Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: The LAAO Italian Multicenter Registry. JACC Cardiovasc Interv. 2018; 11(11): 1086–1092.
  28. Mazzone P, Angelo G, Regazzoli D, et al. 16-27: Percutaneous Left Atrial Appendage Closure with WATCHMAN device: results from the TRAPS Registry. EP Europace. 2016; 18(suppl_1): i7–i7.
  29. Burysz M, Litwinowicz R, Burysz A, et al. Causes of death and morbidity in patients with atrial fibrillation after left atrial appendage occlusion. Kardiol Pol. 2019; 77(11): 1047–1054.



Polish Heart Journal (Kardiologia Polska)